Drugs in Tuberculosis and Leprosy

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The treatment of tuberculosis and leprosy requires the utilization of combination regimens commonly including agents with variable toxicity profiles that may be further exacerbated by drug–drug interactions and patient-specific factors. The increase in incorporation of older and novel agents to treatment regimens has revealed unique adverse effect profiles and added to the previous understanding of these drug's adverse effect profiles. In this chapter we review the pertinent literature from 2017 regarding adverse effects for the following agents: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, delamanid, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thioacetazone.

Original languageEnglish
Title of host publicationSide Effects of Drugs Annual
EditorsSidhartha D. Ray
PublisherElsevier B.V.
Pages363-376
Number of pages14
ISBN (Print)9780444641199
DOIs
StatePublished - 1 Jan 2018

Publication series

NameSide Effects of Drugs Annual
Volume40
ISSN (Print)0378-6080

Fingerprint

Linezolid
Leprosy
bedaquiline
Tuberculosis
Rifamycins
Thioacetazone
Aminosalicylic Acid
Clofazimine
Cycloserine
Pyrazinamide
Dapsone
Ethambutol
Carbapenems
Fluoroquinolones
Macrolides
Isoniazid
Aminoglycosides
Pharmaceutical Preparations
Peptides
Toxicity

Keywords

  • Adverse effects
  • Ethambutol
  • Isoniazid
  • Leprosy
  • Pyrazinamide
  • Rifamycins
  • Side effect
  • Tuberculosis

Cite this

Ramanathan, M. R., Howell, C. K., & Sanders, J. M. (2018). Drugs in Tuberculosis and Leprosy. In S. D. Ray (Ed.), Side Effects of Drugs Annual (pp. 363-376). (Side Effects of Drugs Annual; Vol. 40). Elsevier B.V.. https://doi.org/10.1016/bs.seda.2018.06.014
Ramanathan, Meenakshi Ravindran ; Howell, Crystal Kay ; Sanders, James M. / Drugs in Tuberculosis and Leprosy. Side Effects of Drugs Annual. editor / Sidhartha D. Ray. Elsevier B.V., 2018. pp. 363-376 (Side Effects of Drugs Annual).
@inbook{f6137ce56e564ffca943cfce45ceeb9e,
title = "Drugs in Tuberculosis and Leprosy",
abstract = "The treatment of tuberculosis and leprosy requires the utilization of combination regimens commonly including agents with variable toxicity profiles that may be further exacerbated by drug–drug interactions and patient-specific factors. The increase in incorporation of older and novel agents to treatment regimens has revealed unique adverse effect profiles and added to the previous understanding of these drug's adverse effect profiles. In this chapter we review the pertinent literature from 2017 regarding adverse effects for the following agents: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, delamanid, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thioacetazone.",
keywords = "Adverse effects, Ethambutol, Isoniazid, Leprosy, Pyrazinamide, Rifamycins, Side effect, Tuberculosis",
author = "Ramanathan, {Meenakshi Ravindran} and Howell, {Crystal Kay} and Sanders, {James M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/bs.seda.2018.06.014",
language = "English",
isbn = "9780444641199",
series = "Side Effects of Drugs Annual",
publisher = "Elsevier B.V.",
pages = "363--376",
editor = "Ray, {Sidhartha D.}",
booktitle = "Side Effects of Drugs Annual",

}

Ramanathan, MR, Howell, CK & Sanders, JM 2018, Drugs in Tuberculosis and Leprosy. in SD Ray (ed.), Side Effects of Drugs Annual. Side Effects of Drugs Annual, vol. 40, Elsevier B.V., pp. 363-376. https://doi.org/10.1016/bs.seda.2018.06.014

Drugs in Tuberculosis and Leprosy. / Ramanathan, Meenakshi Ravindran; Howell, Crystal Kay; Sanders, James M.

Side Effects of Drugs Annual. ed. / Sidhartha D. Ray. Elsevier B.V., 2018. p. 363-376 (Side Effects of Drugs Annual; Vol. 40).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Drugs in Tuberculosis and Leprosy

AU - Ramanathan, Meenakshi Ravindran

AU - Howell, Crystal Kay

AU - Sanders, James M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The treatment of tuberculosis and leprosy requires the utilization of combination regimens commonly including agents with variable toxicity profiles that may be further exacerbated by drug–drug interactions and patient-specific factors. The increase in incorporation of older and novel agents to treatment regimens has revealed unique adverse effect profiles and added to the previous understanding of these drug's adverse effect profiles. In this chapter we review the pertinent literature from 2017 regarding adverse effects for the following agents: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, delamanid, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thioacetazone.

AB - The treatment of tuberculosis and leprosy requires the utilization of combination regimens commonly including agents with variable toxicity profiles that may be further exacerbated by drug–drug interactions and patient-specific factors. The increase in incorporation of older and novel agents to treatment regimens has revealed unique adverse effect profiles and added to the previous understanding of these drug's adverse effect profiles. In this chapter we review the pertinent literature from 2017 regarding adverse effects for the following agents: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, delamanid, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thioacetazone.

KW - Adverse effects

KW - Ethambutol

KW - Isoniazid

KW - Leprosy

KW - Pyrazinamide

KW - Rifamycins

KW - Side effect

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85051781249&partnerID=8YFLogxK

U2 - 10.1016/bs.seda.2018.06.014

DO - 10.1016/bs.seda.2018.06.014

M3 - Chapter

AN - SCOPUS:85051781249

SN - 9780444641199

T3 - Side Effects of Drugs Annual

SP - 363

EP - 376

BT - Side Effects of Drugs Annual

A2 - Ray, Sidhartha D.

PB - Elsevier B.V.

ER -

Ramanathan MR, Howell CK, Sanders JM. Drugs in Tuberculosis and Leprosy. In Ray SD, editor, Side Effects of Drugs Annual. Elsevier B.V. 2018. p. 363-376. (Side Effects of Drugs Annual). https://doi.org/10.1016/bs.seda.2018.06.014